PharVision Advisers’s Arcosa ACA Stock Holding History

PharVision Advisers’s Portfolio ACA Stock Details ACA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,331	Closed	-$218K	–	670
2025 Q3	$218K	Buy	+2,331	New	+$217K	0.12%	436

Other funds holding ACA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's ACA Position: Q4 2025 in Review

PharVision Advisers sold out of Arcosa (ACA) in Q4 2025, closing a stake of 2,331 shares — an estimated $218K sold.

PharVision Advisers first reported a position in ACA in Q3 2025 and held it in 1 quarter. The position peaked at $218K in Q3 2025. 364 funds tracked by Wall St. Rank hold ACA as of Q4 2025.

PharVision Advisers reported no remaining Arcosa position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 2,331 Arcosa shares in Q4 2025, an estimated $218K.
PharVision Advisers first reported a position in Arcosa in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Arcosa position peaked at $218K in Q3 2025.
364 funds tracked by Wall St. Rank held Arcosa as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.